Selecting fit-for-purpose Clinical Outcome Assessments (COAs) using the ePROVIDE databases
Introduction
Clinical outcome assessments (COAs) are tools to capture how patients feel, function, or survive. COAs reflect different perspectives and include Patient-Reported Outcomes (PROs), Observer-Reported Outcomes (ObsROs), Clinician-Reported Outcomes (ClinROs), and Performance Outcomes (PerfOs) measures.
COAs are increasingly important measures used within clinical research and practice to inform healthcare decision-making related to drug approval, reimbursement, and treatment plans. This prominence is evident from the rising number of guidelines published by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) which include COA recommendations over the past 25 years.
The 21st century has also seen an explosion in COA development. This presents opportunities to select COAs rigorously developed COAs that measure well-defined, patient-relevant concepts of interest and for which sufficient evidence supports their use in a specific population and context of use. When appropriately selected, these COAs can help assess the effect of a medical product on a meaningful aspect of health (MAH), defined as an aspect of feeling or functioning in daily life that is important to patients. However, the abundance of available measures also creates challenges in identifying which COAs are fit for a particular purpose.
What is a ‘fit-for-purpose’ COA?
“First, validity is not an off/on, yes/no designation. No test is ‘‘valid’’ or ‘‘not valid.’’ Instead, validity comes in ‘‘degrees.’’ Second, validity is not a property of a test; rather, validity speaks to how a score from a test is interpreted or used” (Edwards et al., 2018)
Selecting a fit-for-purpose COA begins not with the instrument, but with what matters to patients. Researchers should first identify the MAH that the treatment is expected to affect, drawing on patient experience data and other relevant evidence. They can then define the specific concept or concepts of interest that will help assess the MAH, before determining whether a COA and its score can support the proposed interpretation and use within the specific context of use.
Fit-for-purpose as a concept for health outcomes is situated within broader notions of validity. The FDA-National Institutes of Health glossary defines ‘fit-for-purpose’ as “a conclusion that the level of validation associated with a biomarker or COA is sufficient to support its proposed use” (FDA-NIH, 2016).
This definition is closely related to modern validity theory whereby the understanding of validity (and therefore what is fit-for-purpose) is centred around “sufficiency of evidence” (Weinfurt, 2025) for score interpretation. This evidence incorporates the following components according to FDA thinking:
- A clearly defined concept of interest.
- A clearly defined context of use.
- A clear rationale for why the proposed COA should be considered fit-for-purpose.
A COA could therefore be fit-for-purpose for measuring symptoms in one specific population but unfit-for-purpose in a different population since “validity is not a property of a test” (Edwards et al., 2018). Current thinking on what makes a COA fit-for-purpose is therefore focused on assessing the concept of interest and context of use, including the type of population with which validity-related evidence was generated.
How to identify ‘fit-for-purpose’ COAs?
Determining whether a COA is fit-for-purpose requires rigorous evaluation of the rationale and evidence supporting its proposed interpretation and use in a well-defined population and context of use. This includes examining whether the COA adequately measures the intended COI and whether its scores correspond to the MAH that the COI is intended to assess.
Targeted literature reviews can be used to examine this evidence which can be complemented through evaluating regulatory guidelines and product-labeling claims on previous recommendations and applications. The ePROVIDE™ platform can facilitate this review by providing centralized access to information on COAs, regulatory recommendations and labeling precedents. Its three databases support different but complementary aspects of endpoint strategy development:
- PROINSIGHT™ can be used to review over 300 regulatory guidelines on what COAs are recommended for use in different populations and which concepts to measure with these COAs.
- PROLABELS™ provides an overview of which COAs have been used to measure which concepts for different populations in over 2500 product (drug/device) label claims. Once a researcher has an idea about the concepts they are interested in measuring for a specific population and context of use, this information can be cross-referenced in PROQOLID™.
- PROQOLID™ contains over 9500 detailed COA descriptions to help contextualise how the COA is used in practice. This includes licensing, translations, recall period, scoring information etc. as well as understanding whether there is sufficient evidence to support the COAs use to measure the concept of interest in the specific population and context.
Using database-specific filters accelerates the identification of fit-for-purpose COAs which are specific to the needs of studies and patients. In Table 1, elements that are key to consider when searching for a fit-for-purpose COA have been mapped to the PROQOLID™ filters (along with an example) to demonstrate how this resource can be used to narrow down the vast number of available COAs. In this worked example, the MAH is the patient's ability to perform daily activities. It is important to note that not all filters must be deployed when searching for a fit-for-purpose COA and the search criteria should always be adapted to the specific study. Candidate COAs should then be evaluated against the proposed context of use, including their content validity, measurement properties, interpretability, feasibility and evidence supporting the intended score interpretation.
| Table 1: Elements to consider for selecting a fit-for-purpose COA mapped to PROQOLIDTM | |||
| Elements to consider for selecting a fit-for-purpose COA |
PQ filters |
Comments |
Worked example |
| Concept of interest | Concepts of interest* | E.g. HRQoL, patient satisfaction, psychological functioning | Physical functioning |
Domains* | E.g. Specific areas which contribute to the overall measurement of the concept of interest |
Any | |
Context of use (including population) | Therapeutic indication | A specific disease, condition, or symptom | Breast neoplasms |
| Therapeutic area | A group of related diseases and conditions | Neoplasms/Skin and Connective Tissue Diseases | |
| Age category* | E.g. child, adolescent, adult, aged | Adult | |
| Context* | E.g. treatment type | Chemotherapy, Adjuvant (optional) | |
| Type of outcome assessment | E.g. PRO, ObsRO, ClinRO, PerfO | PRO | |
| Modes of administration* | E.g. self-administered, clinician-rated, interview-administered | Self-administered | |
| Data collection mode* | E.g. e-version, paper and pen, telephone-administered | Paper and pen/e-version | |
| Types of devices | E.g. Smartphone, tablet, laptop | Any | |
| Languages* | E.g. any translations that the COA is available in | Any | |
*Filters available through a subscription to PROQOLIDTM, for more information see here.
Conclusion
Selecting a fit-for-purpose COA requires more than identifying a well-known measure or one previously used in the same disease area. The process should begin by identifying an aspect of health that is meaningful to patients and defining the specific concept or concepts of interest that will help assess it. The proposed interpretation and use of the COA scores must then be supported by sufficient evidence within the intended population and context of use.
Selecting a COA will rarely be a simple decision. Researchers need to ensure that the data collected and interepreted to inform healthcare decisions reflect outcomes that matter to patients. This requires careful and rigorous assessment of candidate COAs and the rationale and evidence supporting their proposed use. Resources such as the ePROVIDE™ databases can accelerate these evaluations by centralizing data on COAs and regulatory opinions in one place to facilitate comparison of concepts, populations, and validity-related evidence. Through synthesizing these data, researchers can make more informed decisions about which COAs are the most fit-for-purpose to measure concepts that are meaningful for their patients.
For additional support, reach out to our team of experts in Patient Centered Endpoint Intelligence.
Thank you to Tilly Stott, Associate Outcomes Researcher and Nadine Kraft, Principal, for their contributions to this article.
REFERENCES:
American Psychological Association (2014) Standards for Educational and Psychological Testing. Washington, DC
Cella D, Nolla K, Peipert JD. “The challenge of using patient reported outcome measures in clinical practice: how do we get there?” J Patient Rep Outcomes. 2024 Mar 21;8(1):35
Food and Drug Administration (FDA). (2020) Clinical Outcome Assessment (COA): Frequently Asked Questions. Available at: https://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions [Accessed on 18-06-2025].
Food and Drug Administration (FDA). (2022) “Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for Purpose Clinical Outcome Assessments”. PFDD 3. Available at: https://www.fda.gov/media/159500/download [Accessed on 18-06-2025].
Food and Drug Administration (FDA). (No date) Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Available here. [Accessed on 16-06-2025].
FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Glossary. 2016 Jan 28 [Updated 2025 Jan 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK338448/ Co-published by National Institutes of Health (US), Bethesda (MD).
Edwards MC, Slagle A, Rubright JD, Wirth RJ. “Fit for purpose and modern validity theory in clinical outcomes assessment”. Qual Life Res. 2018 Jul;27(7):1711-1720
Makhni EC, Hennekes ME. “The Use of Patient-Reported Outcome Measures in Clinical Practice and Clinical Decision Making”. J Am Acad Orthop Surg. 2023 Oct 15;31(20):1059-1066
Oehrlein EM; US Food and Drug Administration Interviewees. “An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments”. Value Health. 2023 Jun;26(6):791-795.
Weinfurt, K.P. (2025) “The Argument-Based Approach to Validity Applied to Clinical Outcome Assessments: Some History and Notable Features”. Value in Health, Volume 0, Issue 0.